In This Article:
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where 908 Devices Inc. (NASDAQ:MASS) stands against other healthcare stocks that are surging in 2025.
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.
Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.
Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.
Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified 15 Energy Stocks that are Up the Most in 2025 in another article.
Methodology
For this article, I screened the best-performing healthcare stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A research scientist in a lab wearing safety glasses, surrounded by laboratory equipment testing life science samples.
908 Devices Inc. (NASDAQ:MASS)
Number of Hedge Fund Holders In Q4 2024: 9
908 Devices Inc. (NASDAQ:MASS) creates handheld and desktop devices for chemical analysis, focusing on applications in forensics, drug detection, and public safety.
The most important catalyst was the March 2025 announcement of a strategic transformation, where 908 Devices divested its desktop bioprocessing portfolio to Repligen for $70 million.
This move sharpened the company’s focus on its higher-growth handheld market and nearly doubled its cash reserves. The company also completed the acquisition of RedWave Technology in April 2024, and integrated FTIR products to strengthen its analytical device portfolio, and reported a 19% year-over-year revenue increase for 2024, with fourth quarter revenue up 31%.